Hal Korman will be president of Mylan's generics subsidiary, Mylan Pharmaceuticals, leaving the top job at Mylan's UDL Laboratories. Korman will report to Lou DeBone, who has been heading the generics division in addition to his role as Mylan chief operating officer. John Deiriggi is named Mylan's first VP-generic business development, with responsibility for generic drug business development at all subsidiaries. Deiriggi has been serving as VP-strategic planning...
You may also be interested in...
Amwell’s increased the size of its IPO and raised $742m when it sold 41.2 million shares at $18 each.
Pink Sheet Podcast: COVID-19 Stresses Manufacturing, Vaccine Placebo Controls, Thorny FDA Precedents
Pink Sheet reporters and editor discuss the pandemic’s effects on non-coronavirus-related product manufacturing, US FDA efforts to ensure vaccine sponsors maintain placebo controls once a product is available, and precedents that burden the agency.
While Accord HealthCare has convinced the European Medicines Agency that its rivaroxaban generic should be approved in the EU, Bayer has warned that patent protection for Xarelto continues until at least late 2023. The EMA this week also recommend approval for a number of other new drugs.